Table 1.
Analyses overall and restricted to trials with dual antiplatelet therapy of at least six months
| Variable and stent types | People with diabetes | People without diabetes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All trials | Trials with dual antiplatelet therapy ≥6 months | All trials | Trials with dual antiplatelet therapy ≥6 months | ||||||||
| Hazard ratio (95% CI) | IC* | Hazard ratio (95% CI) | IC* | Hazard ratio (95% CI) | IC* | Hazard ratio (95% CI) | IC* | ||||
| Death overall: | |||||||||||
| SES v bare metal stent | 1.14 (0.74 to 1.60) | 61% | 0.88 (0.55 to 1.30) | 20% | 1.02 (0.77 to 1.29) | 3% | 1.05 (0.69 to 1.73) | 1% | |||
| PES v bare metal stent | 1.09 (0.71 to 1.66) | 0.91 (0.60 to 1.38) | 0.90 (0.67 to 1.16) | 0.89 (0.66 to 1.18) | |||||||
| SES v PES | 1.02 (0.70 to 1.57) | 0.95 (0.63 to 1.43) | 1.13 (0.83 to 1.54) | 1.23 (0.82 to 1.69) | |||||||
| Cardiac death: | |||||||||||
| SES v bare metal stent | 1.09 (0.63 to 1.93) | 24% | 0.80 (0.42 to 1.57) | 4% | 0.88 (0.48 to 1.60) | 10% | 0.93 (0.45 to 1.81) | 12% | |||
| PES v bare metal stent | 1.08 (0.62 to 2.28) | 0.94 (0.52 to 1.87) | 0.90 (0.52 to 1.54) | 0.89 (0.55 to 1.47) | |||||||
| SES v PES | 0.98 (0.46 to 2.08) | 0.85 (0.50 to 1.55) | 0.96 (0.58 to 1.84) | 1.04 (0.54 to 1.95) | |||||||
| Myocardial infarction: | |||||||||||
| SES v bare metal stent | 0.68 (0.44 to 1.05) | 30% | 0.68 (0.43 to 1.12) | 30% | 0.87 (0.64 to 1.20) | 5% | 0.81 (0.55 to 1.14) | 20% | |||
| PES v bare metal stent | 0.84 (0.55 to 1.31) | 0.85 (0.54 to 1.43) | 1.08 (0.74 to 1.51) | 1.05 (0.72 to 1.42) | |||||||
| SES v PES | 0.79 (0.56 to 1.23) | 0.80 (0.55 to 1.27) | 0.81 (0.58 to 1.06) | 0.75 (0.57 to 1.07) | |||||||
| Death or myocardial infarction: | |||||||||||
| SES v bare metal stent | 1.04 (0.75 to 1.61) | 57% | 0.88 (0.57 to 1.27) | 56% | 0.93 (0.71 to 1.13) | 6% | 0.91 (0.69 to 1.13) | 13% | |||
| PES v bare metal stent | 1.07 (0.74 to 1.62) | 0.91 (0.70 to 1.31) | 1.04 (0.84 to 1.31) | 1.00 (0.84 to 1.25) | |||||||
| SES v PES | 0.97 (0.72 to 1.34) | 0.95 (0.69 to 1.27) | 0.90 (0.71 to 1.09) | 0.88 (0.71 to 1.06) | |||||||
| Stent thrombosis (ARC definite): | |||||||||||
| SES v bare metal stent | 0.46 (0.15 to 1.42) | 26% | 0.33 (0.09 to 1.09) | 24% | 1.35 (0.76 to 2.73) | 32% | 1.24 (0.58 to 3.08) | 20% | |||
| PES v bare metal stent | 1.05 (0.32 to 4.01) | 0.82 (0.23 to 3.09) | 1.54 (0.83 to 3.13) | 1.48 (0.69 to 3.40) | |||||||
| SES v PES | 0.44 (0.15 to 1.17) | 0.40 (0.13 to 1.08) | 0.87 (0.47 to 1.69) | 0.84 (0.41 to 1.88) | |||||||
| Stent thrombosis (per protocol): | |||||||||||
| SES v bare metal stent | 0.48 (0.17 to 1.35) | 20% | 0.20 (0.05 to 0.68) | 5% | 1.43 (0.78 to 3.00) | 8% | 1.48 (0.74 to 3.41) | 10% | |||
| PES v bare metal stent | 1.27 (0.38 to 4.91) | 0.73 (0.19 to 2.80) | 1.73 (0.88 to 3.61) | 1.80 (0.89 to 3.67) | |||||||
| SES v PES | 0.38 (0.11 to 1.07) | 0.27 (0.07 to 0.80) | 0.82 (0.44 to 1.73) | 0.82 (0.44 to 1.73) | |||||||
| Target lesion revascularisation: | |||||||||||
| SES v bare metal stent | 0.29 (0.22 to 0.39) | 2% | 0.29 (0.19 to 0.45) | 0% | 0.29 (0.22 to 0.38) | 3% | 0.29 (0.19 to 0.42) | 1% | |||
| PES v bare metal stent | 0.38 (0.28 to 0.55) | 0.38 (0.26 to 0.56) | 0.46 (0.33 to 0.60) | 0.46 (0.32 to 0.60) | |||||||
| SES v PES | 0.76 (0.53 to 1.05) | 0.78 (0.50 to 1.14) | 0.63 (0.49 to 0.82) | 0.64 (0.49 to 0.84) | |||||||
SES=sirolimus eluting stent; PES=paclitaxel eluting stent; ARC=Academic Research Consortium.
*Inconsistency of network expressed as percentage difference in hazard ratios between direct randomised comparisons within trials and indirect comparisons between trials. Values near 0 indicate that all comparisons in network are consistent, showing fully coherent estimates of hazard ratios comparing any two stent types. Values can range from 0% to infinity. The more values deviate from 0%, the more inconsistent the network. A value of 25% may be interpreted to indicate low inconsistency, 50% moderate, and 100% high inconsistency. (Also see table 5 in web extra appendix 3 for 95% credibility intervals and P values of inconsistency estimates.)